Transformation of a prostatic adenocarcinoma into squamous cell carcinoma after luteinizing hormone-releasing hormone (LHRH) agonist and radiotherapy treatment.
Adenocarcinoma
/ pathology
Aged
Antineoplastic Agents, Hormonal
/ administration & dosage
Carcinoma, Squamous Cell
/ pathology
Combined Modality Therapy
Gonadotropin-Releasing Hormone
/ agonists
Humans
Male
Neoplasm Recurrence, Local
Prostatectomy
Prostatic Neoplasms
/ pathology
Triptorelin Pamoate
/ administration & dosage
Prostate
hormonotherapy
squamous cell carcinoma
Journal
The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
06
2019
accepted:
29
06
2019
entrez:
12
3
2021
pubmed:
1
11
2019
medline:
31
3
2021
Statut:
epublish
Résumé
Squamous cell carcinoma of the prostate is rare and represents 0.5% to 1% of prostatic carcinomas. Transformation of prostatic adenocarcinoma into squamous cell carcinoma after LH-RH agonist intake has been reported in only 8 cases in the literature. To our knowledge, our case is the second pure squamous cell carcinoma observed after hormonotherapy and radiotherapy. We reported a case of a patient with prostatic adenocarcinoma treated by radical prostatectomy followed by radiotherapy. Eleven years later, he had a vesical recurrence of prostatic adenocarcinoma. Our patient had an endoscopic resection followed by injections of Triptorelin. Six months later, he developed a local recurrence of a squamous cell carcinoma.
Identifiants
pubmed: 33708294
doi: 10.11604/pamj.2019.34.125.19421
pii: PAMJ-34-125
pmc: PMC7906544
doi:
Substances chimiques
Antineoplastic Agents, Hormonal
0
Triptorelin Pamoate
08AN7WA2G0
Gonadotropin-Releasing Hormone
33515-09-2
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
125Informations de copyright
© Hamza Ichaoui et al.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
J Urol. 1956 Feb;75(2):314-23
pubmed: 13296133
Radiat Oncol. 2007 Apr 03;2:15
pubmed: 17407588
Am J Clin Pathol. 1988 Nov;90(5):597-601
pubmed: 2459960
J Urol. 1979 Jun;121(6):833-5
pubmed: 458967
Hum Pathol. 1991 Oct;22(10):1046-50
pubmed: 1842377
Histopathology. 1990 Oct;17(4):339-44
pubmed: 1701756
Am J Surg Pathol. 2004 May;28(5):651-7
pubmed: 15105655
Urology. 1995 Feb;45(2):329-31
pubmed: 7855985
Urology. 1995 Jul;46(1):111-3
pubmed: 7541581
Rev Urol. 2011;13(1):56-60
pubmed: 21826130
Mod Pathol. 2004 Mar;17(3):316-27
pubmed: 14976541
Prostate Cancer Prostatic Dis. 2000 Jul;3(1):53-56
pubmed: 12497163
Urology. 1991 Mar;37(3):260-2
pubmed: 2000687
Radiol Case Rep. 2019 Feb 11;14(4):483-489
pubmed: 30805072
Int Urol Nephrol. 2005;37(2):311-3
pubmed: 16142562
Urology. 1999 Apr;53(4):832-4
pubmed: 10197870
Diagn Pathol. 2011 May 31;6:46
pubmed: 21627811
Cent European J Urol. 2014;67(1):26-8
pubmed: 24982776
Int J Urol. 2003 Feb;10(2):114-6
pubmed: 12588611